Cannabis, Linked Emotions, and Adolescent Risk Study (NCT06576076) | Clinical Trial Compass
RecruitingNot Applicable
Cannabis, Linked Emotions, and Adolescent Risk Study
United States200 participantsStarted 2025-02-18
Plain-language summary
The goal of this study is to disentangle relationships between acute cannabis use and withdrawal on proximal depression and suicide risk and recovery in adolescents ages 12-18 years by incorporating time-varying patterns of substance use, mood, and SI. This project aims to guide the development of scalable, individualized, accessible, and affordable interventions aimed to reduce depression and suicide risk among adolescents.
Who can participate
Age range
12 Years – 18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Ages 12-18;
* Current daily or near daily cannabis use (i.e., use ≥ 4 days per week on average; Timeline Followback);
* Score ≥ 5 on PHQ-9;
* Access to an internet-capable smartphone (iOS or Android);
* Provision of at least 1 collateral contact for risk monitoring;
* Provision of informed assent (or consent if 18 years or older) and parent/guardian consent if \<age 18;
* Greater than 50% response rate to EMA prompts during the first EMA phase;
* No immediate plan to discontinue cannabis use in the next 3 months;
* Positive toxicology result for cannabis on baseline urinalysis.
Exclusion Criteria:
* Any factor that impairs ability to comprehend and effectively participate, including acute intoxication at time of consent;
* Cannabis use \>4 times/day on average (to maximize likelihood of capturing mood and SI during non-use times);
* Inability to speak/write English fluently;
* Gross cognitive impairment, for example due to florid psychosis, intellectual disability, developmental delay, or neurodegenerative disease;
* Current epilepsy diagnosis;
* Individuals who are under the legal protection of the government or state (wards of the state);
* Response of "No" to the knowledge check question regarding EMA suicidality response time;
* Inability to wear Fitbit device.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Aim 1: Cannabis use in the last hour
Timeframe: Weeks 1 - 2 (EMA Phase 1; Baseline Use as Usual)
2
Aim 1: Motivation to use cannabis to improve mood collected
Timeframe: Weeks 1 - 2 (EMA Phase 1; Baseline Use as Usual)